|
|
 |
|
Viewing report
|
|
|
|
World Generic Market Report 2009
Espicom Business Intelligence Ltd, Jan 2009, Pages: 714
Understand the corporate threats and market opportunities that are shaping this rapidly evolving sector.
This new 2 volume, 714-page edition is packed with facts, figures, analysis and statistics, that provides the most thorough analysis available on generic markets, products and companies and the issues they face.
The changing face of the generics industry:
Corporate consolidation continues to change the operating landscape, most notably with the acquisition of Barr Pharma by Teva which has created by far the largest generics company and a major player on the global pharmaceutical stage. Big though the deal may be, it is just one of a number of events which are seeing the rationalisation of the industry. In a separate and interesting company development, Merck & Co has announced the development of a biosimilar division in the US.
Is the credit crunch taking its toll?:
For some generic players, tighter healthcare budgets may prove an opportunity to boost sales. In contrast, those with high debt levels and restricted access to credit may struggle to survive in their current form.
Key company, market and product information:
To understand the generic market, Espicom, the publisher of the respected twice-monthly business publication World Generic Markets, has published The World Generic Market Report 2009. Packed with facts, figures, analysis and statistics, the new 2 volume 714-page edition provides the most thorough analysis available on generic markets, products and companies and the issues they face.
Industry consolidation, company survival, new market opportunities, the latest on biosimilars plus much more!:
Published in January 2009, this report draws on primary research with companies, statistics offices, health ministries and trade associations worldwide and provides standard, comparative data and discussion on key issues such as:
- Industry consolidation and the emergence of “super” generic companies
- Generic market growth – but where?
- Biosimilars: continued development in Europe but no action in US – will the new Obama government break the deadlock?
- Are changes afoot in EU generic regulation?
- Key legal challenges
- The political and funding background
- Intellectual property issues
Product samples
Samples for this product is available. Please Login/Register to download these samples.
Customers who bought this item also bought
The World Generic Market Report 2008
Generic Handbook: A Guide to the Generic Drug Industry in the US, 2007 Edition
European Generic Drug Market Potential
Emerging Generic Pharmaceuticals Markets in Europe
Generic Series: An Introduction To The Canadian Generics Market - Key Trends And Leading Companies Shaping The Market
Generic Strategies in Emerging Markets
Generic Drug Market in Canada
Emerging Generic Drug Markets in Europe
Generic Drugs Market in Brazil (2007-2011)
Booming US Generic Drug Market
Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
Agrows Complete Guide to Generic Pesticides: Volume 3, Successful Business Strategies
|
|
|
|
